Quality control, Propranolol HCl, Oral tablets


Objective: The purpose of this study is to evaluate the quality control of marketed tablets containing propranolol hydrochloride available on the Iraqi market and manufactured by different companies.

Methods: Different batches of propranolol hydrochloride 40 mg tablets were assessed using quality control tests. Weight variation, diameter, thickness, friability, disintegration time and dissolution study were carried out in this study.

Results: Based on the data obtained in this study, all brands of PPL available on the Iraqi market showed weight variation within the acceptable limit of USP. Marketed products of Becardin and Propranolol lie within the acceptable limit of hardness and Inderal was observed to be slightly higher than the normal upper range of USP. Diameter and thickness for all brands were almost the same, except the diameter of Becardin was slightly higher and friability was zero for all brands. All brands demonstrated a time of disintegration of fewer than 30 min. The tested marketed propranolol products; Inderal, Procard, Becardin and Propranolol showed cumulative drug release of 90.08%, 94.46%, 92.4% and 79.51%, respectively at the end of the first 20 min. This variation in the release profile of marketed tablets of Propranolol HCl might be attributed to the excipients present in the marketed tablets where some of these excipients may behave as a disintegrant and enhance dissolution rate while others may act as dissolution retardants.

Conclusion: All marketed tablets of Propranolol HCl employed in this study were produced within the standard criteria of tablet manufacturing. Evaluation of quality control of these selected tablets showed acceptable pharmaceutical properties that lie within the limits of USP.


Download data is not yet available.


Lionberger RA, Lee SL, Lee L, Raw A, Yu LX. Quality by design: concepts for ANDAs. Am assoc. Pharm Sci. 2008;10(2):268-76.

Jameel F, Hershenson S, Khan MA, Martin Moe S. Quality by design for biopharmaceutical drug product development. 1st ed. Springer; 2015.

Q8. (R2): Pharmaceutical development. Part I: Pharmaceutical development, and Part II: annex to pharmaceutical development; 2009.

Fahmy R, Kona R, Dandu R, Xie W, Claycamp G, Hoag SW. Quality by design I: Application of failure mode effect analysis (FMEA) and plackett–burman design of experiments in the identification of ”main factors” in the formulation and process design space for roller-compacted ciprofloxacin hydrochloride Immediat. Am assoc. Pharm Sci. 2012;13(4):1243-54.

Rajora A, Chhabra G. Quality by design approach: regulatory need, current, and future perspective. Asian J Pharm Clin Res. 2021;14(6):29-35. doi: 10.22159/ajpcr.2021.v14i6.33733.

Harde H, Das M, Jain S. Solid lipid nanoparticles: an oral bioavailability enhancer vehicle. Expert Opin Drug Deliv. 2011;8(11):1407-24. doi: 10.1517/17425247.2011.604311, PMID 21831007.

Thulluru A, Sai VK, M PK, BR. Effect of effervescence in combination with superdisintegrants in the formulation of propranolol HCl oral disintegrating tablets. Asian J Pharm Clin Res. 2017;10(3):227-34. doi: 10.22159/ajpcr.2017.v10i3.16096.

Loyd Allen HCA. Ansel’s pharmaceutical dosage forms and drug delivery systems. 10th ed. Lippincott Williams & Wilkins; 2013.

Kumar S, M AM, Kumar S, Kumar A. Comparative bioequivalence studies of cinnarizine and its different available marketed formulation drugs. Asian J Pharm Clin Res. 2020;13(6):209-15. doi: 10.22159/ajpcr.2020.v13i6.37384.

Ramakrishna S, Mihira V, Vyshnavi K, Ranjith V. Design and evaluation of drug release kinetics of meloxicam sustained release matrix tablets. Int J Curr Pharm Res. 2012;4(1):90-9.

Lahai M, Conteh EBS, Mansaray AF, Amara J, Bawoh M, Komeh JP, Tejan-kella A, Sesay M, Johnson WCN. Evaluation of the quality of different brands of ascorbic acid in Freetown, Sierra Leone. Int J Pharm Pharm Sci. 2021;13(9):22-6. doi: 10.22159/ijpps.2021v13i9.41230.

Hettiarachchi TW, Wickramaratne M, Sudeshika T, Niyangoda D, Sakeena MHF, Herath HMDR. Comparative in vitro evaluation of metformin HCl and paracetamol tablets commercially available in Kandy District, Sri Lanka. Int J Pharm Pharm Sci. 2015;7(2):520-4.

Stott PW, Williams AC, Barry BW. Mechanistic study into the enhanced transdermal permeation of a model β-blocker, propranolol, by fatty acids: a melting point depression effect. Int J Pharm. 2001;219(1-2):161-76. doi: 10.1016/s0378-5173(01)00645-7, PMID 11337176.

Gordon MS. Process considerations in reducing tablet friability and their effect on in vitro dissolution. Drug Dev Ind Pharm. 1994;20(1):11-29. doi: 10.3109/03639049409047211.

Parrot E, Saski W. Solid pharmaceuticals. In: Experimental pharmaceutical technology. 3rd ed. Minneapolis: Burgess Publishing Co.; 1971.

Narang AS, Badawy SIF. editors. Handbook of pharmaceutical wet granulation: theory and practice in a quality by design paradigm. 1st ed. Academic Press; 2018.

Sarfaraz N. Textbook of biopharmaceutics and clinical pharmacokinetics. Appleton-Century-Crofts; 1979.

Lieberman H, Lachman L, Schwartz JB, editors. Pharmaceutical dosage forms: tablets. 2nd ed. Vol. 1. CRC Press; 1989.

Karmakar P, Kibria MG. In vitro comparative evaluation of quality control parameters between paracetamol and paracetamol/caffeine tablets available in Bangladesh. Int Curr Pharm J. 2012;1(5):103-9. doi: 10.3329/icpj.v1i5.10282.

Conceicao AP, Sa RR, da Silva VC, Ferreira MdS, Cazedey ECL, Magalhaes HIF, Santos Junior AdF. A comparative study of propranolol release by in vitro dissolution profiles in pharmaceutical formulations. Diss Technol. 2018;25(4):54-61. doi: 10.14227/DT250418P54.

Mahato RI, Narang AS. Pharmaceutical dosage forms and drug delivery. 3rd ed. CRC Press; 2017.

Shuma ML, Biswas BK, Raihan SZ, Halder S. In vitro comparative dissolution studies of different propranolol generic tablets available in Bangladesh. J Drug Delivery Ther. 2021;11(6-S):86-91. doi: 10.22270/jddt.v11i6-S.5225.



How to Cite

ABDUL-HASAN, M. T., MOHAMMED JAWAD, K. K., NEAMAH Al-SHAIBANI, A. J., & HASAN AL-GBURI, K. M. (2022). QUALITY EVALUATION OF BRANDS OF PROPRANOLOL HCL TABLETS AVAILABLE ON IRAQI MARKET. International Journal of Applied Pharmaceutics, 14(2), 48–52. https://doi.org/10.22159/ijap.2022v14i2.43756



Original Article(s)

Most read articles by the same author(s)